<SEC-DOCUMENT>0001157523-22-001182.txt : 20220906
<SEC-HEADER>0001157523-22-001182.hdr.sgml : 20220906
<ACCEPTANCE-DATETIME>20220906060057
ACCESSION NUMBER:		0001157523-22-001182
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20220905
FILED AS OF DATE:		20220906
DATE AS OF CHANGE:		20220906

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Innate Pharma SA
		CENTRAL INDEX KEY:			0001598599
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39084
		FILM NUMBER:		221226727

	BUSINESS ADDRESS:	
		STREET 1:		117 AVENUE DE LUMINY
		STREET 2:		BP 30191
		CITY:			MARSEILLE
		STATE:			I0
		ZIP:			13009
		BUSINESS PHONE:		33430303030

	MAIL ADDRESS:	
		STREET 1:		117 AVENUE DE LUMINY
		STREET 2:		BP 30191
		CITY:			MARSEILLE
		STATE:			I0
		ZIP:			13009

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Innate Pharma, SA
		DATE OF NAME CHANGE:	20140129
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a52857138.htm
<DESCRIPTION>INNATE PHARMA S.A. 6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Business Wire
         Document created using EDGARfilings PROfile 8.4.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><br>
    <div>
      <div style="text-align: center; margin-right: 6.25pt; margin-left: 6.9pt; margin-top: 4.5pt; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">UNITED STATES</div>
      <div style="text-align: center; margin-right: 6.25pt; margin-left: 6.9pt; margin-top: 0.1pt; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
      <div style="text-align: center; margin-right: 198.8pt; margin-left: 199.6pt; margin-top: 0.1pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Washington, D.C. 20549</div>
      <div style="text-align: center; margin-right: 198.8pt; margin-left: 199.6pt; margin-top: 0.1pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; margin-right: 198.8pt; margin-left: 199.6pt; margin-top: 0.1pt; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">FORM 6-K</div>
      <div style="text-align: center; margin-right: 198.8pt; margin-left: 199.6pt; margin-top: 0.1pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; margin-right: 6.75pt; margin-left: 6.9pt; margin-top: 0.5pt; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
        THE SECURITIES</div>
      <div style="text-align: center; margin-right: 6.75pt; margin-left: 6.9pt; margin-top: 0.5pt; font-weight: bold;">EXCHANGE ACT OF 1934</div>
      <div style="margin-top: 0.35pt;"><br>
      </div>
      <div style="text-align: center; margin-right: 163.55pt; margin-left: 163.6pt; font-weight: bold;">Date of report: For the month of September 2022</div>
      <div style="text-align: center; margin-right: 163.55pt; margin-left: 163.6pt; font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; margin-right: 163.55pt; margin-left: 163.6pt; font-weight: bold;">Commission File Number: 001-39084</div>
      <div style="text-align: center; margin-right: 163.55pt; margin-left: 163.6pt; font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; margin-right: 6.75pt; margin-left: 6.75pt; margin-top: 0.05pt; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">Innate Pharma S.A.</div>
      <div style="text-align: center; margin-right: 6.75pt; margin-left: 6.75pt; margin-top: 0.45pt;">(Translation of registrant's name into English)</div>
      <div style="margin-top: 0.3pt;"><br>
      </div>
      <div style="text-align: center; margin-right: 6.75pt; margin-left: 6.75pt; font-weight: bold;">Innate Pharma S.A.</div>
      <div style="text-align: center; margin-right: 6.25pt; margin-left: 6.9pt; margin-top: 0.4pt; font-weight: bold;">117 Avenue de Luminy&#8212;BP 30191</div>
      <div style="text-align: center; margin-right: 6.3pt; margin-left: 6.9pt; margin-top: 0.45pt; font-weight: bold;">13009 Marseille, France</div>
      <div style="text-align: center; margin-right: 6.75pt; margin-left: 2.3pt; margin-top: 0.45pt; font-weight: bold;">+ 33 (0) 4 30 30 30</div>
      <div style="text-align: center; margin-right: 6.3pt; margin-left: 6.9pt; margin-top: 0.45pt;">(Address of principal executive office)</div>
      <div style="margin-top: 0.25pt;"><br>
      </div>
      <div style="text-align: justify; margin-top: 0.05pt; font-family: 'Times New Roman',Times,serif;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</div>
      <div style="margin-right: 56.8pt; margin-left: 5.55pt; margin-top: 0.05pt;"> <br>
      </div>
      <div style="text-align: justify; margin-top: 0.05pt; font-family: 'Times New Roman',Times,serif;">Form 20-F [ X ]<font id="TRGRRTFtoHTMLTab" style="display: inline-block; width: 12pt;">&#160;</font>Form 40-F [&#160; ]</div>
      <div style="margin-right: 56.8pt; margin-left: 5.55pt; margin-top: 0.05pt;"> <br>
      </div>
      <div style="text-align: justify; margin-top: 0.05pt; font-family: 'Times New Roman',Times,serif;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
        [&#160; ]</div>
      <div style="margin-right: 34.45pt; margin-left: 5.55pt; margin-top: 0.05pt;"> <br>
      </div>
      <div style="text-align: justify; margin-top: 0.05pt; font-family: 'Times New Roman',Times,serif;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
        [&#160; ]</div>
      <div style="margin-right: 34.45pt; margin-left: 5.55pt; margin-top: 0.05pt;"> <br>
      </div>
      <div style="margin-right: 34.45pt; margin-left: 5.55pt; margin-top: 0.05pt;"> <br>
      </div>
      <div><br>
      </div>
      <div>
        <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-weight: bold;">INCORPORATION BY REFERENCE</div>
      </div>
      <div>
        <div style="text-align: justify; margin-top: 12pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">This Report on Form&#160;6-K&#160;[and Exhibit 99.1 to this Report on Form&#160;6-K]&#160;shall be deemed to be incorporated
          by reference into the registration statement on Form&#160;F-3&#160;(File&#160;No.&#160;333-252074)&#160;of Innate Pharma S.A. (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is
          furnished, to the extent not superseded by documents or reports subsequently filed or furnished.</div>
      </div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center;"><font style="font-weight: bold;">EXHIBIT INDEX</font></div>
      <div style="margin-top: 0.45pt;"><br>
      </div>
      <div style="margin-top: 4.7pt;"><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;"><u> </u></font>
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" id="ze20bf8f6da17470b91aba817d121bbbb">

            <tr>
              <td style="width: 10%;">
                <div><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;"><u>Exhibit</u></font><font id="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; width: 66.45pt;">&#160;</font>
                  <br>
                </div>
              </td>
              <td style="width: 90%;">
                <div><font style="font-weight: bold; font-family: 'Times New Roman',Times,serif;"><u>Description</u></font> <br>
                </div>
              </td>
            </tr>
            <tr>
              <td style="width: 10%;">
                <div>&#160;</div>
              </td>
              <td style="width: 90%;">
                <div>&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 10%;">
                <div><a href="a52857138_ex991.htm"><font style="font-family: 'Times New Roman',Times,serif;">99.1</font></a> <br>
                </div>
              </td>
              <td style="width: 90%;">
                <div><a href="a52857138_ex991.htm">[Press Release dated September 5, 2022]</a> <br>
                </div>
              </td>
            </tr>

        </table>
      </div>
      <div style="margin-left: 5.55pt; margin-top: 4.7pt;"><font id="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; width: 66.45pt;"></font><br>
      </div>
      <div style="margin-top: 0.1pt;"><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center;"><font style="font-weight: bold;">SIGNATURES</font></div>
      <div style="margin-top: 0.3pt;"><br>
      </div>
      <div style="font-family: 'Times New Roman',Times,serif;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
        undersigned, thereunto duly authorized.</div>
      <div style="margin-top: 0.25pt;"><br>
      </div>
      <div style="margin-top: 0.25pt;"><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" id="0a69b9f700f54270817404585a74fab9">

          <tr>
            <td style="width: 50%;">&#160;</td>
            <td style="width: 7%;" colspan="2" rowspan="1"><font style="font-weight: bold;">INNATE PHARMA S.A.</font>&#160; <br>
            </td>
          </tr>
          <tr>
            <td style="width: 50%;" rowspan="1">&#160;</td>
            <td style="width: 7%;" colspan="2" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%;" rowspan="1">&#160;</td>
            <td style="width: 7%;" colspan="2" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; padding-bottom: 2px;"><font style="font-family: 'Times New Roman',Times,serif;">Date: September 5, 2022</font> <br>
            </td>
            <td style="width: 7%; padding-bottom: 2px;" colspan="1"><font style="font-family: 'Times New Roman',Times,serif;">By:</font> <br>
            </td>
            <td style="width: 43%; border-bottom: 2px solid rgb(0, 0, 0);">/s/ Mondher MAHJOUBI <br>
            </td>
          </tr>
          <tr>
            <td style="width: 50%;">&#160;</td>
            <td style="width: 7%;" colspan="1">Name: <br>
            </td>
            <td style="width: 43%;">Mondher MAHJOUBI <br>
            </td>
          </tr>
          <tr>
            <td style="width: 50%;" rowspan="1">&#160;</td>
            <td style="width: 7%;" colspan="1" rowspan="1"><font style="font-family: 'Times New Roman',Times,serif;">Title:</font> <br>
            </td>
            <td style="width: 43%;" rowspan="1"><font style="font-family: 'Times New Roman',Times,serif;">Chairman of the Executive Board and Chief Executive Officer</font> <br>
            </td>
          </tr>

      </table>
      <br>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a52857138_ex991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Business Wire
         Document created using EDGARfilings PROfile 8.4.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 99.1</font><br>
  </div>
  <div style="text-align: right;"><font style="font-weight: bold;"> <br>
    </font></div>
  <div>
    <div class="bw-release">
      <h1 style="text-align: center; list-style-position: inside;FONT-SIZE: 14pt;"> <b>Innate Pharma to Present Lacutamab PTCL Phase 1b Design and ANKET<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#8482;</sup> Platform at ESMO 2022</b> </h1>
      <div class="bw-release-subhead">
        <ul style="list-style-type: disc;">
          <b>
            <li> <b><i>Poster presentation on ongoing lacutamab Phase 1b trial design in monotherapy in peripheral T-cell lymphoma</i></b> </li>
            <li> <b><i>Oral presentation on multispecific antibodies: ANKET for antigen-specific activation of NK cells by Innate&#8217;s Chief Scientific Officer, Eric Vivier, DVM, PhD,</i></b> </li>
            <li> <b><i>AstraZeneca-sponsored Phase 2 NeoCOAST study of neoadjuvant durvalumab alone or combined with novel agents, including monalizumab, in patients with resectable, early-stage non-small cell lung cancer (NSCLC) accepted for a mini-oral
                  presentation on pharmacodynamic and circulating tumor DNA dynamics in the study</i></b> </li>
          </b>
        </ul>
      </div>
      <div class="bw-release-body">
        <div class="bw-release-table-js bw-release-story">
          <p>MARSEILLE, France--(BUSINESS WIRE)--September 5, 2022--Regulatory News: </p>
          <p> Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (&#8220;<b>Innate</b>&#8221; or the &#8220;<b>Company</b>&#8221;) today announced that the following presentations will be presented at the ESMO (European Society for Medical Oncology) Annual Meeting 2022 taking
            place from 9 to 13 September 2022, in Paris, France. </p>
          <ul style="list-style-type: disc;">
            <li> <b>A multi-center Phase Ib trial evaluating the safety and efficacy of lacutamab in patients with relapsed/refractory peripheral T-cell lymphoma that express KIR3DL2 <br>
              </b>- Abstract Number: 647TiP <br>
              - Session Type: Trial In Progress Poster <br>
              - Session Title: Haematological malignancies <br>
              - Session Date: Sunday Sept 11, 2022 <br>
              - Presenter: Marianna Muller, MD, PharmD, Clinical Development Director at Innate Pharma </li>
          </ul>
          <ul style="list-style-type: disc;">
            <li> <b>Oral presentation: Designing multispecific antibodies: ANKET for antigen-specific activation of NK cells <br>
              </b>- Session Type: Special session <br>
              - Session Title: Next frontiers in drug discoveries <br>
              - Date and Time: Monday Sept 12, 2022 9:05 AM - 9:20 AM CEST <br>
              - Location: 7.3.U - Urval Auditorium <br>
              - Presenter: Eric Vivier, DVM, PhD, Chief Scientific Officer of Innate Pharma </li>
          </ul>
          <ul style="list-style-type: disc;">
            <li> <b>Oral presentation: Platform study of neoadjuvant durvalumab (D) alone or combined with novel agents in patients (pts) with resectable, early-stage non-small-cell lung cancer (NSCLC): pharmacodynamic correlates and circulating tumor DNA
                (ctDNA) dynamics in the NeoCOAST study [AstraZeneca-sponsored] <br>
              </b>- Presentation #929MO <br>
              - Session Type: Mini Oral Session <br>
              - Session Title: Non-metastatic NSCLC and other thoracic malignancies <br>
              - Date and Time: Monday Sept 12, 2022 3:15 PM CEST <br>
              - Location: 7.3.O - Orl&#233;ans Auditorium <br>
              - Presenter: Jonathan Spicer (Montreal, Canada) </li>
          </ul>
          <div> </div>
          <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" id="DSPFPageBreakArea">
            <div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
              <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
          </div>
          <p> The poster and presentations will be available on the Publications section of innate-pharma.com following the presentation. </p>
          <p> <b>About Lacutamab:</b> </p>
          <p> Lacutamab (IPH4102) is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody that is currently in clinical trials for treatment of cutaneous T-cell lymphoma (CTCL), an orphan disease, and peripheral T cell lymphoma (PTCL).
            Rare cutaneous lymphomas of T lymphocytes has a poor prognosis with few efficacious and safe therapeutic options at advanced stages. </p>
          <p> KIR3DL2 is an inhibitory receptor of the KIR family, expressed by approximately 65% of patients across all CTCL subtypes and expressed by up 90% of patients with certain aggressive CTCL subtypes, in particular, S&#233;zary syndrome. It is
            expressed by up to 50% of patients with mycosis fungoides and peripheral T-cell lymphoma (PTCL). It has a restricted expression on normal tissues. </p>
          <p> <b>About ANKET<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#8482;</sup>:</b> </p>
          <p> ANKET<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#8482;</sup> (<b>A</b>ntibody-based <b>NK</b> cell <b>E</b>ngager <b>T</b>herapeutics) is Innate's proprietary platform for developing next-generation, multi-specific natural killer (NK) cell engagers to treat certain types of cancer.
          </p>
          <p> This versatile, fit-for-purpose technology is creating an entirely new class of molecules to induce synthetic immunity against cancer. It leverages the advantages of harnessing NK cell effector functions against cancer cells and also provides
            proliferation and activation signals targeted to NK cells. </p>
          <p> Our latest innovation, the tetra-specific ANKET molecule, is the first NK cell engager technology to engage activating receptors (NKp46 and CD16), a tumor antigen and an interleukin-2 receptor (via an IL-2 variant, IL-2v) via a single
            molecule. </p>
          <p> <b>About Monalizumab:</b> </p>
          <p> Monalizumab is a potentially first-in-class immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor infiltrating cytotoxic CD8+ T cells and NK cells. </p>
          <p> NKG2A is an inhibitory checkpoint receptor for HLA-E. By expressing HLA-E, cancer cells can protect themselves from killing by NKG2A+ immune cells. HLA-E is frequently overexpressed in the cancer cells of many solid tumors and hematological
            malignancies. Monalizumab may reestablish a broad anti-tumor response mediated by NK and T cells, and may enhance the cytotoxic potential of other therapeutic antibodies<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup>. </p>
          <p> The ongoing development for monalizumab is focused on investigating monalizumab in various combination strategies in different malignancies, including, in early lung cancer, the Phase 3 PACIFIC-9 study in adults with locally advanced (Stage
            III), unresectable NSCLC, who have not progressed following platinum-based concurrent chemoradiotherapy, and the Phase 2 NeoCOAST-2 study in the neoadjuvant early-stage setting of NSCLC. </p>
          <div> </div>
          <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" id="DSPFPageBreakArea">
            <div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
              <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
          </div>
          <p> <b>About Innate Pharma:</b> </p>
          <p> Innate Pharma S.A. is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. </p>
          <p> Innate Pharma&#8217;s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need. </p>
          <p> Innate is a pioneer in the understanding of Natural Killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified
            proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca. </p>
          <p> Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US. </p>
          <p> Learn more about Innate Pharma at www.innate-pharma.com </p>
          <p> <b>Information about Innate Pharma shares:</b> </p>
          <table cellspacing="0" id="z44261554f2324205a40f29875810e726" style="margin-bottom: 10px;margin-left: 0px; margin-right: auto; font-size: 10pt;">

              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: top;padding-left: 0px;">
                  <p style="text-align: left;margin-bottom: 0px; margin-top: 0px;"> <b>ISIN code</b> </p>
                </td>
                <td colspan="1" rowspan="1"><br>
                </td>
                <td colspan="1" rowspan="1"><br>
                </td>
                <td colspan="1" rowspan="1"><br>
                </td>
                <td colspan="1" rowspan="1"><br>
                </td>
                <td colspan="1" rowspan="1"><br>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: top;padding-left: 0px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;"> FR0010331421 </p>
                </td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: top;padding-left: 0px;">
                  <p style="text-align: left;margin-bottom: 0px; margin-top: 0px;"> <b>Ticker code</b> </p>
                </td>
                <td colspan="1" rowspan="1"><br>
                </td>
                <td colspan="1" rowspan="1"><br>
                </td>
                <td colspan="1" rowspan="1"><br>
                </td>
                <td colspan="1" rowspan="1"><br>
                </td>
                <td colspan="1" rowspan="1"><br>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: top;padding-left: 0px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;"> Euronext: IPH Nasdaq: IPHA </p>
                </td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: top;padding-left: 0px;">
                  <p style="text-align: left;margin-bottom: 0px; margin-top: 0px;"> <b>LEI</b> </p>
                </td>
                <td colspan="1" rowspan="1"><br>
                </td>
                <td colspan="1" rowspan="1"><br>
                </td>
                <td colspan="1" rowspan="1"><br>
                </td>
                <td colspan="1" rowspan="1"><br>
                </td>
                <td colspan="1" rowspan="1"><br>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: top;padding-left: 0px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;"> 9695002Y8420ZB8HJE29 </p>
                </td>
              </tr>

          </table>
          <p> <b>Disclaimer on forward-looking information and risk factors:</b> </p>
          <p> This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including &#8220;believe,&#8221; &#8220;potential,&#8221; &#8220;expect&#8221; and &#8220;will&#8221; and
            similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which
            could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results
            from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company&#8217;s commercialization efforts and the Company&#8217;s continued ability to raise capital to fund
            its development. For an additional discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please
            refer to the Risk Factors (&#8220;Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (&#8220;AMF&#8221;), which is available on the AMF website http://www.amf-france.org or on Innate Pharma&#8217;s
            website, and public filings and reports filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;), including the Company&#8217;s Annual Report on Form 20-F for the year ended December 31, 2021, and subsequent filings and reports filed with the
            AMF or SEC, or otherwise made public, by the Company. </p>
          <div> </div>
          <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" id="DSPFPageBreakArea">
            <div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
              <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
          </div>
          <p> This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country. </p>
          <p> <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup> Andr&#233; et al, Cell 2018 </p>
        </div>
        <div class="bw-release-contact">
          <h2 style="FONT-SIZE: 14pt;">Contacts</h2>
          <p> <b>For additional information:</b> </p>
          <p> <b><u>I</u></b><u><b>nvestors and Media</b></u> </p>
          <p> <b>I</b><b>nnate Pharma </b><br>
            Henry Wheeler <br>
            Tel.: +33 (0)4 84 90 32 88 <br>
            Henry.wheeler@innate-pharma.fr </p>
          <p> <b>ATCG Press </b><br>
            Delphine Lens (France) <br>
            Tel.: +33 (0)9 81 87 46 72 <br>
            innate-pharma@atcg-partners.com </p>
        </div>
      </div>
    </div>
    <font style="font-weight: bold;"> </font></div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
